RxSight, Inc.
No SEC Form 4 filings for $RXST in the last 30 days.
See all $RXST insider activity →Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.
Simply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.
Over the past 7 days, alphai's AI scored 3 news stories mentioning RXST (RxSight, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent RXST coverage spans financial news, technology and earnings.
The deal extends RxSight’s technology into a broader PCIOL offering, potentially expanding addressable market and royalty revenue streams.
Simply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
Near-term earnings visibility worsens due to guidance withdrawal, while Alcon collaboration revenue partially offsets weaker core product sales.
The Alcon partnership is a meaningful validation catalyst for RxSight’s premium LAL platform, but near-term fundamentals remain loss-making with declining revenue.
The 8-K combines quarterly financials with a guidance withdrawal, plus a CEO transition and a next-gen platform announcement, which can reset near-term expectations.
alphai scores every news story that mentions RXST with an AI model for sentiment and relevance, and aggregates insider trades from RxSight, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.
3 min readSimply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
6 min readRxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.
6 min readAlcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST) announced a non-exclusive collaboration to co-develop post-operative adjustable pseudophakic intraocular lenses using RxSight’s light-adjustable technology. Alcon also opened a second training center in India with Aravind. Q1 2026: Alcon net sales $2.7B (+10% YoY), core EPS $0.85, FCF $279M. RxSight revenue $30.9M (-18.5% YoY), net loss $15.9M, gross margin 76.1%.
6 min readRxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, a
6 min readRxSight, Inc. said filings show Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander beneficially own 3,030,287 shares, or 7.3% of the common stock class, as of June 30, 2026. The entities report shared voting and dispositive power, with a Joint Filing Agreement dated Aug. 3, 2026.
2 min readRxSight says its Light Adjustable Lens (LAL) has been implanted in more than 325,000 cases and is now available in Australia after inclusion on the ARTG. The company describes a post-surgery “test drive” using UV light treatments to fine-tune refractive outcomes, with up to three adjustments and final “lock-in” therapy. RxSight reports over 2,000 surgeons using the LAL internationally.
6 min readRxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.
3 min readRxSight (NASDAQ: RXST) said it granted new CEO Aziz Mottiwala inducement equity awards on July 24, 2026. The package includes stock options for 571,286 shares with a $5.19 exercise price and RSUs for 2,312,138 shares. Options vest 25% at one year then monthly, while RSUs vest 20%, 20%, then 60% over three years.
4 min readSimply Wall St reports RxSight (RXST) fair value fell from $9.93 to $8.43 after softer Q2 trends and a guidance cut. It cites Jefferies lowering its price target to $6.50 (Hold) and BofA cutting to $6.50 (Underperform). BofA notes Alcon collaboration potential; Jefferies points to below-expected preliminary Q2 results and utilization at a four-year low.
5 min read
